Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoChoice-informed chemotherapy in metastatic NSCLC
NCT06576635Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel, Paclitaxel Micelles for Injection, gemcitabine, pemetrexed and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by University of Illinois Chicago. Primary endpoint: Objective Response Rate. Started Dec 2024; status: recruiting.
02
Drugs
docetaxelPaclitaxel Micelles for Injectiongemcitabinepemetrexedvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06576635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576635.